Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (9593)	6/13/1998 1:32:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

blankmind, The script data does not come out first thing in the morning. I think the price of the stock will run up to 7 1/2 in the morning in anticipation of a sharp increase of script numbers. Once the numbers come out to confirm this, we should see a move to about 8 or higher. If Vivus comes out with an effective press release after the numbers are confirmed we may even be able to push 9. Remember, daily averages have already increased last week. Data on next Monday will reflect news on Viagra which was negative. Based on the news released over the past week, many doctors will avoid prescribing Viagra to patients who are not only on nitro type meds, but also any type of high blood pressure medication. At this point in time it is simply too risky for these doctors to prescribe Viagra in conjunction with high blood pressure medications. Even the media which has generally been very pro Viagra is now seriously questioning the probable dangers of severe hypotention when mixing Viagra with high blood pressure medications. Expect Pfizer to relable Viagra to add a long list of high blood pressure meds which should not be used in conjunction with Viagra. This will completely bust open the pool of ED men who will try MUSE as a second alternative thus giving the MUSE script numbers an even larger boost. It is just a matter of time now before the investment community realizes that Vivus at 7 is about 1/3 fair value when looking at future earnings 3 to 6 months out.